Lu-177-PSMA-617 vs Jevtana (cabazitaxel): which should I do next?

Posted on February 15, 2021 by Sitemaster

We saw recently (see this link) that of chemotherapeutic and hormonal medicines for treatment of metastatic castration-resistant prostate cancer (mCRPC), Jevtana (cabazitaxel) is the preferred third-line treatment after Taxotere (docetaxel) and Zytiga (abiraterone acetate) or Xtandi (enzalutamide). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 3 Comments »

FDA approves lower dose of cabazitaxel in treatment of mCRPC

Posted on September 15, 2017 by Sitemaster

Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a comment »

Differing chemotherapies and their effects in the treatment of mCRPC

Posted on August 25, 2017 by Sitemaster

The results of two recent, large clinical trials may have some impact on the clinical use of cabazitaxel (Jevtana) in the treatment of late-stage prostate cancer. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 3 Comments »

NHS to stop covering cost of cabazitaxel for mCRPC as of November

Posted on September 8, 2015 by Sitemaster

As reported in a wide spectrum of media over the past few days (see here for example), on Friday last week the National Health Service announced that it would no longer cover the costs associated with use of cabazitaxel (Jevtana) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC) through the UK’s Cancer Drugs Fund — effective as of November 1, 2015. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | 8 Comments »

Tasquinimod + cabazitaxel in heavily pre-treated men with mCRPC

Posted on January 23, 2012 by Sitemaster

According to media information from Active Biotech this morning, the company has initiated an early stage, combination therapy trial (the so-called CATCH trial) of their investigational agent tasquinimod + cabazitaxel (Jevtana®) for the treatment of men with heavily pre-treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | Leave a comment »

Cabazitaxel gets final approval for marketing in Europe

Posted on March 21, 2011 by Sitemaster

According to a media release from Sanofi-Aventis, the European Commission has authorized marketing of cabazitaxel (Jevtana®) in all 27 countries of the European Union in combination with prednisone or prednisolone. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , | 4 Comments »

European Medicines Agency approves cabazitaxel

Posted on January 21, 2011 by Sitemaster

According to a media release from Sanofi-Aventis and a report on the Reuters web site today, the European Medicines Agency (EMEA) has approved cabazitaxel (Jevtana) … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | Leave a comment »

Report provides final results of the TROPIC trial of cabazitaxel

Posted on October 2, 2010 by Sitemaster

Cabazitaxel (Jevtana®) has recently been approved in the USA for the treatment of men with castration-resistant prostate cancer who have progressive disease following treatment with standard first-line chemotherapy (docetaxel + prednisone). … READ MORE …

Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: , , | 1 Comment »

US FDA approves cabazitaxel for late-stage prostate cancer

Posted on June 17, 2010 by Sitemaster

Somewhat “out of the blue,” the US Food and Drug Administration (FDA), earlier today, approved Sanofi-Aventis’s “second-generation” taxane, cabazitaxel (Jevtana®) in combination with prednisone for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , | 2 Comments »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives